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Summary in three easy slides (no math, no theory)
Limitations of traditional medicine
Requirements for predictive and personalized medicine
Potential of systems biology
Canonical modeling
Illustration:  Parkinson’s disease (preliminary)
Challenges and state of the art
Limitations of Traditional Medicine
Humpty Dumpty
Sat on a wall.
Humpty Dumpty
Had a great fall.
All the King’s horses 
And all the King’s men
Couldn’t put Humpty
Together again.
Limitations of Traditional Medicine??
Leslie Wesley 
Lived a good life,
But started to tremble
At age 65.




Claim:     S   ystems Biology May Help!
How does Medicine Work?
Injury (e.g., bone fracture):
Fix problem approximately; nature takes care of rest
Chronic Disease (e.g., diabetes, Parkinson’s):
o Symptoms evident; root causes often not
o Epidemiology associates disease with risk factors or 
biomarkers (high BP, cholesterol, …), based on 
statistics, using population averages
o Lab Science associates disease with mechanisms, based 
on animal experiments, using population averages
What’s the Problem with Averages?
Average input information allows 
average predictions at best
But:  Our goal is to make predictions for 
specific individuals
o with respect to personal health risks
(predictive health)
o with respect to personal diagnostics
and treatment (personalized medicine)
What is Required Then?
Need to progress from average input-output
correlations to a deeper understanding 




Hope:  Analogy with engineering
We do not need to take apart every machine
we encounter, if we understand the principles
that make this type of machine functional.
What is Required Then?
Need to progress from average input-output
correlations to a deeper understanding 




Hope:  Analogy with engineering
We do not need to take apart every machine
we encounter, if we understand the principles
that make this type of machine functional.
Understanding Design Principles
In Biology and Medicine
Strategy:
o “Look under the hood”
o Collect, identify, characterize all components
o Quantify processes and interactions
o Put all into integrative models
o Study average behavior of these models
o Study effect of each component, process
o Trace abnormalities (diseases) to possible root causes
o Develop (in the model) strategies of counteraction
o Validate and use




































Formulation of a Model 
for Complex Systems
Michael Savageau, 1969: Thou shall approximate in log space!






























−+ ∑∑ −== ijijii VVdt
dXX&
Generalized Mass Action Form:































































































































































Why not Use “True” Rate Functions
Realistic Situation: Where to Start?
Task:  Assess with a model the importance of genetic 
predisposition in Parkinson’s Disease
A priori, no guidelines for model design
Physical (first) principles too far removed
Gene expression too coarse
Little overlap between metabolic and neurological modeling
How to incorporate “soft” clinical information:





−+ ∑∑ −== ijijii VVdt
dXX&
GMA Form: ∑ ∏±= ijkfjiki XX γ&
Canonical Models: No Panacea,








ii XXXXXXX ++ ++ β−α= ,21,21  ... ... 2121&
Which variable affects which flux? 
How strongly? Influence positive or negative?
Model guaranteed to be locally good.
Advantage: Standardized Analyses
Model Design: Strict guidelines 
Domain of Representation:  All nonlinearities possible
Steady-State Analysis: Existence, stability, sensitivities
Dynamics: Optimized, customized software tools
Optimization (e.g., Metabolic Engineering): Often linear
Design and Operating Principles:  Powerful methods
Model Results:  Clear interpretation
X1 X 2 X 3 X 4









Unique Meaning of Parameters
Pathways: purines, glycolysis, citric acid, TCA, red blood cell,
trehalose, sphingolipids, ...
Genes: circuitry, regulation,…
Genome:  explain expression patterns upon stimulus
Growth, immunology, pharmaceutical science, forestry, ...
Metabolic engineering:  optimize yield in microbial pathways
Dynamic labeling analyses possible
Math:  recasting, function classification, bifurcation analysis,...
Statistics:  S-system representation, S-distribution, trends;






3. Many stimuli and agents 
regulate several enzymes 
of lipid metabolism 
4. Some in vivo experiments
Doable Size
Alvarez, Sims , Hannun, Voit
JTB, 2004; Nature, 2005
Estimation of parameter values is complicated and time 
consuming
Typical procedure:  
Characterize every step (process) biologically
Formulate as power-law function
Determine parameter values
Merge all process descriptions
Check system description against “global” data
Crucial Issue
Vi =Ri (Si , Mi )
p1 , p2 , p3 , …
= fk (Xj , Vi )
dXj
dt
Flow Chart of 
Traditional Modeling Strategy
Voit, Drug Discovery Today, 2004
• Use information at the “global” level (in vivo time series 
data) to deduce (per model) structure and regulation at the 
“local” level (connectivity, signals,…)
Alternative to Traditional Modeling:
Top-Down Modeling
∏∏ −= hg XXX βα&
∏∏ −= '' '' hg YYY βα&




Estimation from Time Series Data
o According to computer scientists:  trivial, solved.
o Many methods
o Most work sometimes
o None works always
o Estimation remains to be a challenging topic!
o Example:  Kikuchi et al. 2003
o For canonical models, parameter estimation 
leads to pathway structure identification
Recent Approaches to Parameter
Estimation from Time Series Data
o Substitution of slopes for differentials; including
decoupling of equations (Voit and Savageau, 1982)
o Neural networks, Genetic algorithms (U.S.A., Japan, Portugal)
o Nonlinear regression (U.S.A., Spain)
o Interval methods (Switzerland, Sweden, England)
o Newton flow methods (Switzerland, Sweden, England)
o Simulated Annealing (Germany)
o Swarm methods (Philippines)
o Global branch-and-bound methods (U.S.A.)
o Collocation and hybrid evolution (Taiwan)
o Alternating regression (U.S.A., Norway)





























Not all metabolites and enzymes are known
Not all regulatory signals are known
Parameters are uncertain
Concentrations are uncertain
Flux rates are uncertain
Example: Dopamine Metabolism
Addressing the Parameter Challenge:
Expert Opinion
Ask question in a new fashion:
Not: What is the concentration of DOPAC?
What is the turnover rate of this step?
But: Are concentrations of X and Y about the same?
How do fluxes relate at this branch point? 
Defaults 
Kinetic orders in BST are within small ranges
Restrict ranges based on experience 
with enzyme kinetics
Diagnostics
Massive sensitivity and robustness analysis
Illustration:  Parkinson’s Disease
Work with Zhen Qi, Gary Miller, Mahlon Delong, and others at Emory University.  
Supported by a Predictive Health / Woodruff Foundation Pilot Grant
o Collect information on dopamine metabolism
o Discuss topology of the pathway: “network”
o Discuss regulation of the network: “system”
o Construct symbolic systems equations, using 
Biochemical Systems Theory (BST)
o Guestimate order-of-magnitude concentrations
o Guestimate order-of-magnitude fluxes
o Construct numerical equations
o Diagnose, refine model
BST Formulation (excerpt)
beta1_01 = a1_0 *J1 /(Xs1^h1_1_01  Xs10^h1_10_01  Xs50^h1_50_01 Xs2^h1_2_01 >>  
>> Xs3^h1_3_01  Xs14^h1_14_01  Xs30^h1_30_01)
beta1_02 = a1_0 *J2 /(Xs1^h1_1_02  Xs52^h1_52_02  Xs2^h1_2_02)
beta1_03 = a1_0 *J3 /(Xs1^h1_1_03  Xs52^h1_52_03  Xs2^h1_2_03)  //to Dopaquinone # X52
beta1_04 = a1_0 *J4 /(Xs1^h1_1_04  Xs59^h1_59_04  Xs3^h1_3_04)  //to Tyramine # X59
X1' = a1_0    - beta1_01  X1^h1_1_01  X10^h1_10_01  X50^h1_50_01  X2^h1_2_01  
>> X3^h1_3_01  X14^h1_14_01  X30^h1_30_01 >>
>> - beta1_02  X1^h1_1_02  X52^h1_52_02  X2^h1_2_02 >>
>> - beta1_03  X1^h1_1_03  X52^h1_52_03  X2^h1_2_03 >>




//X10' = alpha10  X1^h1_1_01  X10^h1_10_01  X50^h1_50_01  X2^h1_2_01  X3^h1_3_01  
>> X14^h1_14_01  X30^h1_30_01 >>
>> - beta10  X1^h1_1_01  X10^h1_10_01  X50^h1_50_01  X2^h1_2_01  




beta11 = (alpha11  Xs1^h1_1_01  Xs10^h1_10_01  Xs50^h1_50_01  Xs2^h1_2_01  
>> Xs3^h1_3_01  Xs14^h1_14_01  Xs30^h1_30_01) /(Xs11^h11_11)
X11' = alpha11  X1^h1_1_01  X10^h1_10_01  X50^h1_50_01  X2^h1_2_01  X3^h1_3_01  
>> X14^h1_14_01  X30^h1_30_01 >>
>> - beta11 X11^h11_11
//==============================================================================
Selected Results
Effects of changes in enzyme






































Dynamic responses of 
metabolite concentrations




Manipulation Metabolites Experimental Result Prediction 
dopamine No change -2.68% 
DOPAC No change 0.78% TH heterozygote 
HVA No change -0.94% 
dopamine -99.58% -100.00% 
DOPAC Not detected -100.00% TH knockout 
HVA Not detected -100.00% 
dopamine 6.93% 18.56% 
DOPAC 10.54% 18.93% COMT heterozygote 
HVA -14.52% -49.10% 
dopamine 10.64% 37.39% 
DOPAC 232.95% 464.06% COMT knockout 
HVA -100.00% -100.00% 
dopamine 21.97% 14.57% 
DOPAC 71.46% 89.78% COMT heterozygote + 90% DAT inhibition HVA -17.01% -43.36% 
dopamine 30.58% 30.25% 
DOPAC 447.50% 876.77% COMT knockout + 90% DAT inhibition HVA -100.00% -100.00% 
dopamine -85.42% -89.98% 
DOPAC -58.00% -28.96% VMAT2 LO# 
HVA -58.17% -83.55% 
 
Toward Personalization
o Pathway diagram shows generic “topology” of 
dopamine metabolism (including regulation).
o Parameter values (so far) represent average values 
(e.g., of enzyme activities) in healthy population.
o In reality, enzyme activities and metabolite 
concentrations exhibit interpersonal variability.
o Assumption is made that the model structure is 
robust toward this variability (valid for slightly 
changed parameter values).
o If so, model can be “personalized” by letting some 
values deviate from population averages.
Toward Personalization (cont’d)
o Assume for simplicity that enzyme activities vary 
independently from one another (assumption easy to 
relax).
o Establish distribution for each enzyme activity and each 
concentration within a population (measure or math).
o Then: population variability can be assessed by 
repeatedly drawing a value from each distribution and 
analyzing model responses (“Monte Carlo simulation”).
o Determine “risk factors” through sensitivity analysis.
o Show that some people get sick without exhibiting risk 
factors and others do not get sick in spite of them.
Personal Risk Profiles
Illustration (under the assumption that our model is correct):
Study increases in toxic species 3-MT and dopamine quinone)
DA to 3-MT: h_32
DA to DOPAL: h_31
Personal Risk Profiles
Person h3_1 h3_2 3-MT Dopamine
Quinone
1 √ √ √ √





























Computation of All Risk Profiles
Attempt to look at singular and multiple “aberrations” and 
studied output.       “Combinatorial Explosion”
BST modeling allows elegant assessment of all healthy 
and all pathological profiles.
Mathematical approach:  Using BST (S-system) 
representation, invert steady-state matrix or perform 
straightforward (linear) constrained optimization.
Solution:  One “Simplex” each.
Ideal Solution (in full “biomarker space”):  
Clear separation between health and disease simplexes 

















Projection onto a lower-dimensional biomarker space








Would like to say:  x < ϑ
 
: healthy; x > ϑ
 
: sick
(like PSA > 4)
ϑ







z Result: complex grey “area”
In reality, there is no unique ϑ
 
because disease status
also depends on other biomarkers, such as y and z.
Computation of All Risk Profiles








Computation of All Risk Profiles




A good systems model characterizes 
all these features (simplexes, 
arrows, ranges).
Opportunities
Extend from metabolism to physiology
Define “health” and “disease”
Define “biomarker” and “pre-morbid”
Characterize trajectories toward disease
Study personalized treatment regimens
6-Thioguanine 
e.g.: UA ⇓ ⇒ Xa ⇑
e.g., PRPPS superactivity
or, HGPRT deficiency














































































Degrees of Difficulty for 










For Leslie Wesley it may be too late.
But hopefully, in two thousand and twenty eight,
We have enough data, computers and wisdom
To figure out this complex system.
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